1,542
Views
9
CrossRef citations to date
0
Altmetric
Targeted drugs

Incidence and risk of rash to mTOR inhibitors in cancer patients – a meta-analysis of randomized controlled trials

, &
Pages 124-132 | Received 06 Mar 2014, Accepted 03 May 2014, Published online: 10 Jun 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Lingaku Lee, Tetsuhide Ito & Robert T. Jensen. (2018) Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence. Expert Opinion on Pharmacotherapy 19:8, pages 909-928.
Read now
Azam Roohi & Mohammad Hojjat-Farsangi. (2017) Recent advances in targeting mTOR signaling pathway using small molecule inhibitors. Journal of Drug Targeting 25:3, pages 189-201.
Read now
Kevin Y. Xu, Raji Shameem & Shenhong Wu. (2016) Risk of hyperglycemia attributable to everolimus in cancer patients: A meta-analysis. Acta Oncologica 55:9-10, pages 1196-1203.
Read now

Articles from other publishers (6)

Christoph Hertzberg & David Neal Franz. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy 3721 3751 .
Amy E. Blum & Susan Burgin. (2021) Eczematous Drug Eruptions. American Journal of Clinical Dermatology 22:3, pages 349-366.
Crossref
Catherine Ludwig, Vivien Goh, Jeffrey Rajkumar, Jeremiah Au & Maria Tsoukas. (2020) Drug eruptions associated with tumor therapy: Great imitators. Clinics in Dermatology 38:2, pages 208-215.
Crossref
Christoph Hertzberg & David Neal Franz. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy 1 32 .
Christopher J.E. Watson & Menna R. Clatworthy. 2019. Kidney Transplantation - Principles and Practice. Kidney Transplantation - Principles and Practice 261 282 .
Erica Fischer-Cartlidge, Dina DiCenso, Mary Buckley & Rosalie Villanueva. (2016) CE. AJN, American Journal of Nursing 116:10, pages 28-36.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.